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Abstract
Androgen independence is the major cause of
endocrine therapy failure in advanced prostate cancer
(PC). To examine the effects of human androgen
receptor (AR) expression on growth of human PC
cells, transfection of full-length AR cDNA in an
androgen-insensitive human prostatic adenocarcino-
ma cell line (DU145) was performed. Transcriptional
activity of AR was confirmed by the MMTV luciferase
assay and AR expression was assessed by reverse
transcriptase polymerase chain reaction, Western
blotting, and immunocytochemistry. Two stable trans-
fectant cell lines expressing functional AR were
established and passaged over 60 times. Under
standard culture conditions, AR expression in trans-
fected cells was predominantly cytoplasmic. Expo-
sure to dihydrotestosterone (DHT; 60 pM–10 nM)
resulted in a rapid (maximal at 30 minutes) trans-
location of AR to the nucleus. Treatment with DHT
(5 nM) caused a significant reduction in cell–cell
adhesion and aggregation accompanied by a decrease
in E-cadherin expression. This was associated with up
to 40% inhibition of proliferation and approximately
two-fold increase in apoptosis. These results suggest
that gene transfer–mediated AR expression in DU145
cells confers sensitivity to DHT, modulates cell–cell
adhesion through E-cadherin, and suppresses cell
growth by inhibiting proliferation and promoting apop-
tosis. This provides amodel for studies of AR-regulated
cell signalling and identification of novel androgen-
regulated genes in PC.
Neoplasia (2003) 5, 347 –361
Keywords: androgen receptor; ligand; prostate cancer; E-cadherin; apoptosis.
Introduction
Prostate cancer (PC) is the second commonest cause of
cancer-related deaths in males in the western world and a
steep rise in its incidence has occurred in the last two
decades [1]. Prostatic epithelial cells are androgen-
dependent and eliminating or reducing endogenous
androgens by surgical or chemical castration results in sub-
jective and objective improvements in approximately 80% of
patients with PC [2,3]. This effect, however, lasts only for a
median period of f2 years, after which death follows within 6
to 12 months [4,5]. Androgen ablation results in the inhibition
of cell proliferation and apoptotic cell death in androgen-
dependent PC cells [6–8].
Androgens mediate their effect on target cells through bind-
ing to the high-affinity intracellular androgen receptor (AR), a
member of the steroid receptor superfamily that belongs to a
larger family of ligand-dependent transcription factors [9]. AR is
essential for normal male sexual differentiation and prostatic
epithelial cell proliferation [10]. Upon ligand binding, cytoplas-
mic AR undergoes dimerization, leading to exposure of its
DNA-binding domain. This receptor– ligand complex is then
translocated to the nucleus, where it regulates the transcription
of target genes through androgen-responsive elements in the
promoter regions [11,12]. Structurally or functionally abnormal
ARs may be responsible for altered sensitivity to androgens or
ligand-independent activation, resulting in the development of
androgen independence (AI) [13,14]. The underlying molecular
mechanisms governing the development of AI in human PC are
still not clearly understood [15]. Possible contributing factors
include amplification, deletions, or mutations in the AR gene
[16–23].
Sex steroids (both androgens and estrogens) are also
known to modulate cell–cell adhesion in a tissue-specific and
cell type–specific manner [24–28]. There are few data inves-
tigating the role of androgens in the modulation of expression of
cell–cell adhesion molecules, including E-cadherin [24]. E-
cadherin, a calcium-dependent transmembrane protein, is the
dominant epithelial cell adhesion molecule and a member of a
large family of cell–cell adhesion molecules. It is found in
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adherens junctions where it undergoes homophilic binding
[29,30]. E-cadherin interacts with a group of cytoplasmic
proteins including a-, h-, and g-catenin. h- and g-catenin
bind directly to the E-cadherin cytoplasmic tail and a-catenin
binds to either h- or g-catenin in a mutually exclusive com-
plex. a-Catenin links the E-cadherin complex to the cytoske-
leton through its interaction with actin filaments [29–33]. In
human PC, a decrease in E-cadherin expression is associ-
ated with tumor progression [34,35].
Experimental studies into themechanisms underlying AR-
mediated control of gene transcription are limited because of
the lack of human PC cell lines that contain stable and
functional (nonmutated) AR. Most data are derived from
studies on the LNCaP human PC line, which was derived
from a lymph node metastasis [36]. This contains a mutated
AR [13,37], which is activated not only by androgens but also
by estrogen, progesterone, and antiandrogens [14].
The aim of this study was, therefore, to develop an in
vitro model that would enable investigation of the mecha-
nism of androgen-mediated fate of PC cells. Specifically,
our aims were to: 1) establish an androgen-responsive
phenotype in a hitherto AI cell line (DU 145); 2) assess
the effect of dihydrotestosterone (DHT) on AR localization;
and 3) determine the influence of ligand-mediated activation
of AR on cell behavior including cell–cell adhesion, cell
growth, and apoptosis.
Materials and Methods
All chemicals were of molecular biology grade and were
purchased from Sigma (Poole, UK), unless otherwise
stated.
Cell Culture and Reagents
The DU145 cell line and the LNCaP cell line were pur-
chased from the American Type Culture Collection (ATCC;
Rockville, MD). DU145 cells and its derivatives were main-
tained in minimal essential medium (MEM) containing
Earle’s salts (Gibco BRL, Paisley, UK). LNCaP cells were
cultured in RPMI medium (Cancer Research UK, London,
UK). Both types of media were supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, and 1% antibiotics/
antimycotics (Gibco BRL). Cell cultures were maintained at
37jC in a humidified 10% CO2 atmosphere.
Steroid-stripped FBS (ssFBS) was prepared by adding 1 g
of dextran-coated charcoal into 100 ml of FBS and agitated
on a rolling platform overnight at room temperature. After
centrifugation at 6000g for 15 minutes, the serum was trans-
ferred to a fresh tube and 1 g of dextran-coated charcoal was
added. Following agitation for 6 to 8 hours, the serum was
spun again and filtered through a 0.22-Am filter.
DHT was purchased form Sigma-Aldrich (Poole, UK).
4-Hydroxyflutamide (4-OH-F), a nonsteroidal AR antago-
nist, was a kind gift from AstraZeneca (Lund, Sweden).
A mouse monoclonal antibody (MAB) against E-cadherin
(HECD1; supernatant or affinity-purified) was obtained from
Cancer Research UK; MABs against AR (clone F39.4.1) and
a-, h-, and g-catenins were purchased from Biogenex
(Wokingham, UK) and Transduction Laboratories (Calne,
UK), respectively.
Construction of Human AR Encoding Mammalian
Expression Plasmid
A full-length wild-type human AR cDNA containing a
plasmid, psVARo, was a kind gift from Dr. A. O. Brinkmann
(Department of Endocrinology, Erasmus University, The
Netherlands). Full-length AR cDNA was excised at SalI sites
and ligated into the pSP73 multiple cloning vector (cat. no.
P2221; Promega, Southampton, UK) at SalI sites. A clone
containing AR cDNA in the correct orientation was identified
by restriction enzyme analysis and named pSP73-AR.
pSP73-AR was digested at BamHI and XhoI sites to obtain
af3096-bp AR cDNA-containing fragment, which was then
ligated between BamHI and XhoI sites of pcDNA3.1/zeo
(Invitrogen, Paisley, UK) to achieve an AR-encoding expres-
sion plasmid, pcAR3.1. This plasmid contains a CMV
enhancer promoter and zeocin-resistant gene, which allows
selection of stable transfectants in the presence of cytotoxic
concentrations of zeocin. The integrity of pcAR3.1 and the
presence and orientation of insert were confirmed by exten-
sive restriction analysis and plasmid sequencing. For trans-
fection experiments, plasmid DNA was prepared and
purified using a Maxi prep DNA kit (Qiagen, Crawley, UK).
Stable Transfection of DU145 Cell Line
A modified calcium phosphate method (Stratagene,
Amsterdam, The Netherlands) was employed for stable
transfection of the DU145 cell line. Briefly, cells were plated
overnight in 5-cm tissue culture dishes (Nunc, Nottingham,
UK) at 30% to 40% confluency. The following day, cells in
each dish were fed with 5 ml of 10% FBS medium, and either
5Ag of pcAR3.1 or pcDNA3.1/zeo (control vector) was added
(in mixture with transfection reagents). Transfections were
carried out for 7 hours in a humidified atmosphere at 37jC
and 5% CO2. Thereafter, cells were washed twice with warm
(37jC) phosphate-buffered saline (PBS) and refed with fresh
10% FBS medium. Zeocin selection (300 Ag/ml) was applied
after another 24 hours. After 3 weeks of continuous zeocin
exposure, a number of zeocin-resistant colonies were ring-
cloned and expanded. Initial screening for AR expression
was performed using immunocytochemistry (ICC). One con-
trol transfectant, Dzeo1, and two AR transfectants, DAR17
and DAR19 (which expressed AR immunoreactivity in close
to 100% of cells) were selected for further studies.
RNA Extraction From Cell Lines
Total cellular RNA was extracted from DAR17, DAR19,
and Dzeo1 cell lines and a positive control, LNCaP, using
RNAzol B (Biogenesis, Poole, UK) according to a protocol
described by Stubbs et al. [38]. Briefly, cells grown to approx-
imately 80% confluency in 90-mm tissue culture dishes were
washed with three changes of PBS and drained, and 3 ml of
RNAzol B was added for 5 minutes. The resultant lysates
were transferred into Eppendorf tubes, 200 Al of chloroform
was added, and the mixture vortexed and iced for 5 minutes.
After centrifugation at 10,000g at 4jC for 15 minutes, the
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upper aqueous (RNA containing) phase was transferred into
a fresh tube and an equal volume of isopropanol was added,
mixed gently, placed on ice for 15 minutes, and centrifuged
again under the same conditions. The supernatant was
aspirated and the RNA pellet washed with 75% ethanol, dried
at 65jC for 5 minutes, and resuspended in 20 Al of diethyl
pyrocarbonate (DEPC)–treated water. The yield was deter-
mined spectrophotometrically at 360 nm.
Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR)
Total RNA (2 Ag) was denatured at 70jC for 10 minutes
and chilled on ice for 2 minutes. cDNA was synthesized from
2 Ag of denatured RNA in 50mMTris–Cl, pH 8.3, 75mMKCl,
10 mM dithiothreitol, 3 mM MgCl2 (Gibco BRL), 40 U of
RNAsin (ribonuclease inhibitor; Promega), 500 mM dNTPs
(Promega), 1 ml of oligo(dT)12–18 (Gibco BRL), and 50 U of
StrataScriptase (Stratagene, Amsterdam, Netherlands) in a
final volume of 20 Al. This mixture was incubated at 37jC for
1 hour and the resultantRNA/cDNAwasstored at20jCuntil
required. PCR for both AR and glyceraldehyde phosphate
dehydrogenase (GAPDH) consisted of 100 ng of cDNA,
10mMTris–Cl (pH9),50mMKCl,0.01%gelatinwt/vol,Triton
X-100 (Sigma), and 5 mM of each primer, either AR-specific
(forward primer dAGCTACTCCGGACCTTACG and reverse
primer dAGGTGCCATGGGAGGGTTAG) or GAPDH-
specific (forward primer dGCCACATCGCTCAGACACCA
and reverse primer dGATGACCCTTTTGGCTCCCC),
200 mM dNTPs (Promega), 1.5 mM MgCl2, and 1.5 U of
Taq polymerase (Promega) in a final volume of 25 Al.
Thermal cycling parameters for AR were 94jC for 1 minute;
60jC for 1 minute; 72jC for 3 minutes with a final extension
of 72jC for 10 minutes for 20, 25, 30, or 35 cycles; and for
GAPDH were 94jC for 1 minute; 65jC for 1 minute; and
72jC for 3 minutes for 15, 20, 25, or 30 cycles in a Techne-
PHC3 thermal cycler. PCRproductswere separated on either
a 1% or 1.5% TAE agarose gel, visualized with ethidium
bromide (0.5 mg/ml), and photographed under UV light.
ICC
For ICC, cells were grown on four spot glass slides
(Hendley, Loughton, UK) in standard culture medium or
medium containing ssFBS. Twenty-four hours later, the
medium was aspirated gently and replaced with medium
containing varying concentrations of the AR ligand, DHT
(20 pM–10 nM), or the anti-androgen, 4-OH-F (1 AM). Cells
were incubated for variable lengths of time (15 minutes–
144 hours), washed with PBS, and fixed in a chilled (20jC)
methanol:acetone (1:1) mixture.
Light microscopy An indirect avidin–biotin–peroxidase
complex (ABC) method was used according to the published
protocol by Hsu et al. [39]. Briefly, after blocking of non-
specific binding using normal rabbit serum (1:20 dilution in
PBS; Dako, Ely, UK) for 20 minutes at room temperature,
primary antibody [anti-AR (1:100), anti–E-cadherin (super-
natant; neat), anti–a-catenin (1:50), anti–h-catenin (1:200),
or anti–g-catenin (1:100)] diluted in PBS containing 0.1%
(wt/vol) bovine serum albumin (BSA) (Sigma) (PSA/BSA)
was applied for 2 hours at room temperature in a humidified
chamber. After three washes in PBS, biotinylated rabbit
antimouse antibody (1:200; Dako) was applied for 1 hour
and, subsequently, slides were incubated with avidin–
biotin–HRP complex (1:200; Dako) for 45 minutes at room
temperature. Peroxidase–H2O2 reaction was developed
in 0.3% H2O2 containing 3,3-diamino-benzidine (DAB;
0.5 mg/ml) solution in PBS. Slides were counterstained with
Cole’s hematoxylin.
Immunofluorescence For IF, fixed slides were air-dried,
washed twice in PBS, blocked for 2 hours in antibody buffer
[0.5 M NaCl, 0.05% Tween 20, 1% BSA, and 3% donkey
serum (Dako) in PBS], and incubated with MABs against AR
(1:10; Biogenex) or E-cadherin (affinity-purified; 0.5 Ag/ml)
overnight at 4jC. The second layer of Cy-3–conjugated
donkey antimouse IgG (1:300; Jackson ImmunoResearch
Laboratories, Soham, UK) was applied for 1 hour at room
temperature. Slides were then washed and mounted in
Vectashield containing nuclear dye DAPI (Vector Laborato-
ries, Peterborough, UK). Images were captured using a
digital camera system (Axiocam, Kingston, UK).
For both techniques, a negative control consisted of the
application of nonimmune serum as a first layer.
Western Blotting
For preparation of protein lysates, 2106 cells (in dupli-
cate) in 90-mm tissue culture dishes were plated in 10 ml of
culture medium containing F5 nM DHT (final concentration)
for 24 or 48 hours. Cells were washed twice with PBS and
lysed in situ by addition of 0.5 ml of lysis buffer (715 mM 2-h-
mercaptoethanol, 10% glycerol, 2% SDS, 40 mM Tris, pH
6.8, 1 mM EDTA). The resulting lysate was boiled for 10
minutes with periodic vortexing, iced for 5 minutes, and
centrifuged at 12,000 rpm at 4jC for 5 minutes. Clear super-
natant was aspirated carefully and stored at 70jC until
used. Approximately 20 Ag of total cellular proteins (quanti-
fied spectrophotometrically at 595 nm) fromeach sample was
subjected to sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (100 V for 2 hours), proteins were transferred to
nitrocellulosemembranes, and themembraneswere blocked
with 5% nonfat milk in Tris-buffered saline solution containing
0.5% Tween 20 (TBST) for 1 hour at room temperature.
The blots were then probed overnight with anti-AR MAB
(1:500 in TBST), washed in TBST for 1 hour, and probed
with HRP-conjugated rabbit antimouse immunoglobulins
(1:1500 dilution; Dako). The blots were placed in Enhanced
Chemoluminescent solution (ECL; Amersham, Little Chal-
font, UK) and exposed to X-ray film (Hyperfilm; Amersham).
Densitometric Analyses
Protein bands were analyzed using Personal Densitom-
eter SI (Molecular Dynamics, Hercules, CA) linked to a
Macintosh (Power Macintosh 8100). Gel images were ana-
lyzed with the software program IPLAB gel. Briefly, separate
readings were taken for each band; each reading is the sum
of pixel intensity for a fixed pixel area (rectangular). For each
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band, pixel intensities were averaged and background read-
ings were subtracted (measurement taken as above) to give
average band intensity.
Transient Transfections and Analysis of Reporter
Gene Expression
Twenty four hours after subculturing in 50-mm dishes AR
and control transfectants (1105 cells of each cell line)
were incubated with 2.5 Ag of pSV h-galactosidase (h-gal;
Promega) and 5 Ag of MMTV luc (a kind gift from Dr. A. O.
Brinkmann, Department of Endocrinology, Erasmus Univer-
sity, The Netherlands) plasmids (using above mentioned
protocol for transfection) for 7 hours in a humidified incubator
at 37jC and 5% CO2, washed twice in PBS, and refed with
standard medium. The following day, cells were fed with
media containing dextran charcoal stripped FBS for 24 hours,
and then either 5 nM DHT or 1 AM 4-OH-F was added for a
further 24 hours. The cells were harvested by incubating in
300 Al of reporter lysis buffer (Promega) for 15 minutes and
scraping all the cells and cellular debris into an Eppendorf.
The sample was vortexed for 15 seconds and spun at
16,060g (13,000 rpm) for 2 minutes at 4jC in minifuge.
Samples (supernatants) were either used immediately or
stored at 70jC.
For h-gal assay (Promega), cell extract (150 Al) was
mixed with 150 Al (2) of assay buffer (120 mM Na2HPO4,
80 mM NaH2PO4, 2 mMMgCl2, 100 mM h-mercaptoethanol,
and 1.33 mg/ml ONPG (O-nitrophenyl-h-D-galactopyrano-
side) by vortexing and incubated at 37jC overnight. The
reaction was stopped by the addition of 500 Al of 1 M sodium
carbonate and the absorption was read at 420 nm in a
spectrophotometer. A sample that had not been transfected
with pSV h-gal was used as a negative control. The values
were used to assess transfection efficiency and to normalize
samples (data not shown).
For luciferase (luc) assay (Promega), 5 to 20 Al of cell
extracts was mixed with 100 Al of luc assay buffer (Promega)
(20 mM tricine; 1.07 mM (MgCO3)4Mg(OH)2.5H2O;
2.67 mM MgSO4, 0.1 mM EDTA, pH 7.8, 33.3 mM DTT,
270 AM coenzyme A, 470 AM luciferin, 530 AM ATP) and
immediately counted on a scintillation counter (Beckman LS
1801). The light produced was measured for 1 minute and
the data were analyzed as counts per minute. The value
obtained from a sample that had not been transfected with
MMTV luc was used to calculate the background reading,
which was then deducted from each result.
MTT Cell Proliferation/Viability Assay
MTT cell proliferation/viability assays were conducted in
96-well tissue culture plates (Nunc). Briefly, 5103 cells/well
in 200 Al of medium with or without 5 nM DHT (final concen-
tration) were plated in quadruplicate. Plates were kept at
37jC in 10% CO2 in a humidified incubator. Cells were
assayed daily for reduction of MTT for five consecutive days.
Fifty microliters of MTT (2.5 mg/ml) was added into each well
and plates were kept for 4 hours at 37jC in a humidified
incubator. Medium was removed by gently inverting the
plates. A mixture of 100 Al of dimethylsulphoxide (DMSO;
BDH, Lutterworth, UK) and 25 Al of glycine buffer (pH 10.5)
was added into each well and plates were kept on an orbital
shaker for 10 minutes to develop and homogenize color.
Plates were read in an ELISA plate reader (BioRad 550,
Hemel Hempstead, UK) at 540 nm.
FACS Analysis
For cell cycling, the cell lines Dzeo1, DAR17, and DAR19
were seeded into 5-cm culture dishes and grown in the
presence of 5 nM DHT for 0, 1, 3, and 6 days. The cells
were washed twice in PBS, harvested in versene only, and
washed in PBS. The cells were fixed in 70% ice-cold
ethanol on ice for 1 hour, washed in PBS, and counted,
and 2106 cells were used. The cells were incubated with
1 ml of 5 Ag/ml propidium iodide (PI) and 0.25 mg/ml RNAse
1 for 30 minutes at 37jC before being transferred to Falcon
tubes and analyzed on a cell sorter (Beckman Coulter XL
flow cytometer, High Wycombe, UK).
For E-cadherin, cells were harvested using versene only
after reaching 80% confluency, spun at 400g, and resus-
pended in PBS containing 1% FBS. After obtaining a single
cell suspension, cell viability and number were counted using
trypan blue and 1106 viable cells were used per reaction
and always kept on ice. The cells were then washed three
times using 1% FBS/PBSA and spun at 400g for 1 minute to
pellet the cells. Affinity-purified anti–E-cadherin (HECD1)
was added at 10 Ag/ml in 50 Al of PBS containing 1% FBS
and incubated on ice for 45 minutes prior to washing three
times in 1% FBS in PBSA and pelleting the cells at 400g. An
FITC-labelled rabbit antimouse secondary antibody (Dako)
was added to the samples at 1:40 dilution in 500 Al of PBS
containing 1%FBS and incubated for 45minutes on ice. After
three washes in 1% FBS/PBSA, the cells were resuspended
in 1 ml of 1% FBS/PBSA, transferred to Falcon tubes,
and analyzed on a cell sorter (Beckman Coulter XL flow
cytometer). The integrity of E-cadherin was maintained by
addition of 1 mM calcium chloride to the FBS/PBSA through-
out the experiment [40]. To assess the effects of 5 nM DHT
and 1 AM 4-OH-F on cell adhesion molecule expression,
these agents were added to the standard medium 24 hours
prior to harvesting the cells. The LNCaP cell line known to
express E-cadherin was used as a positive control.
Trypan Blue Exclusion Assay
For the determination of viable and nonviable cell count,
cells grown in the presence and absence of 5 nM DHT
were harvested at 1, 3, and 6 days. Both adherent and
floaters were pelleted by centrifugation and resuspended in
3-ml culture medium. A 10-Al aliquot of this suspension
was mixed with an equal volume of trypan blue solution
(0.4%; Sigma). The viable and nonviable cells were
counted using a hemocytometer.
Cell Death Detection ELISA
A cell death ELISA kit (Boehringer Mannheim, Bracknell,
UK) was used to detect the cytoplasmic fraction of histone-
bound oligonucleosomal fragments as described by Lalani
et al. [41]. Briefly, 105 cells from DHT-treated (5 nM) and
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nontreated cultures were taken at 1, 3, and 6 days and
subjected to lysate preparation according to manufacturer’s
instructions. Experiments were conducted in 96-well micro-
titer plates. Triplicate wells for each lysate were coated with
100 Al of antihistone antibody for 1 hour at room temperature,
washed three times with wash buffer, and blocked with
incubation buffer for 30 minutes. After removing the incuba-
tion buffer, the plates were incubated with 100 Al of cell
lysates per well (representing 104 cells) for 90 minutes at
room temperature.Wells werewashed three times, 3minutes
each, with wash buffer and then incubated with an anti-DNA
antibody conjugated with peroxidase (anti-DNA POD) for
1 hour. After three washes with the wash buffer, color was
developed using 2,2V-azino-di-[3-ethylbenzothiazoline sulph-
onate] (ABTS) (a chromogenic substrate for peroxidase) for
20 minutes and the plate was read on the ELISA plate reader
at 405 nm.
Cell Aggregation Assay
Single cell suspensions of the transfected cell lines were
obtained using versene only, as described previously. The
cells were washed in MEM/1% FBS and counted. About
1105 cells were resuspended in 3 ml of MEM/1% FBS
(contains Ca2+) or PBSA/1% FBS (no Ca2+) and incubated
in a shaking incubator at 37jC for 1 hour. The number of
single cells was counted using a hemocytometer and the
results were presented as the cell aggregation index (number
of cells remaining single divided by total) over time. To assess
the effects of DHT and 4-OH-F on cell aggregation, 5 nMDHT
and/or 1 Am 4-OH-F was added to the media for 18 hours
before initiation of the experiment and was included in the
MEM/1% FBS during the incubation. The absence of DHT
was tested by growing the cells in media containing 10%
ssFBS and repeating the experiment in this media. To test
whether the aggregation effect was mediated by E-cadherin,
the cells were incubated with 10 Ag/ml affinity-purified
HECD1 for 30 minutes prior to starting the aggregation.
Immunoprecipitation
Dzeo1, DAR17, and DAR19 were seeded into 150-mm
culture dishes and grown to 80% confluency in standard
medium, standard medium supplemented with 5 nM DHT
for 18 hours, or standard medium supplemented with 1 Am
4-OH-F for 18 hours prior to being harvested. The cells
were washed three times in PBSA, which was completely
removed, and 5 ml of nondenaturing immunoprecipitation
buffer (0.5% Triton-X, 50 mM NaCl, 10 mM PIPES, pH 6.9,
3 mM MgCl2, 300 mM sucrose) was added. The dishes
were placed on ice for 30 minutes with occasional
rocking. The dishes were scraped and the cells were
placed in 15-ml Falcon tubes, which were placed on ice
for a further 30 minutes with gentle vortexing. The samples
were transferred to Eppendorfs and spun at 13,000 rpm for
10 minutes at 4jC. The supernatant was transferred to a
fresh Eppendorf and stored at 70jC, or processed imme-
diately. The samples were spun again for 30 minutes at
13,000 rpm at 4jC and the supernatant transferred to a
fresh Eppendorf. To each 1-ml sample, 1 Ag of antibody
(either affinity-purified HECD1, anti–a-catenin, anti–h-cat-
enin, anti–g-catenin, or rabbit antimouse IgG; Dako) was
added and the tubes were rotated at 4jC overnight. The
following morning, Sepharose G beads were prepared by
washing twice in buffer 2 (0.1% Triton-X, 15 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 5 mM EDTA, pH 8.0, 2.5 mM
EGTA, pH 8.0). Each sample (supernatant/antibody mix)
was added to 50 Al of prepared beads and placed on a
rotator at 4jC for 2 hours after which the beads/antibody
complexes formed were harvested by spinning at 13,000
rpm at 4jC. The beads were washed and retained twice in
buffer 2, once in buffer 3 (15 mM Tris–HCl, pH 7.5, 0.5 M
NaCl, 5 mM EDTA, 2.5 mM EGTA), and once in buffer 4
(50 mM Tris–HCl, pH 6.8, 5 mM EDTA). After removal of
buffer 4 from the beads, 25 Al of 1 lysis buffer (715 mM
2-h-mercaptoethanol, 10% glycerol, 2% SDS, 40 mM Tris,
pH 6.8, 1 mM EDTA) was added to the beads and the
samples boiled for 5 minutes. The samples were spun and
the supernatant containing the dissociated immunocom-
plexes was subjected to Western blotting and probed with
anti–E-cadherin (Transduction Laboratories).
The data were assessed for statistical significance by
t-tests and a P value of <.05 was considered to be significant.
Results
Morphological Assessment of Transfectants
The only observable difference between the AR trans-
fectants (DAR17 and DAR19) compared to the control,
Dzeo1, was that the cells did not grow as tightly packed
together (cell–cell), which was more noticeable when DHT
was added to the growth medium (Figure 1, A and B). All the
transfectants have been passaged over 60 times and main-
tained the above pattern of growth.
Analysis of AR Expression
RT-PCR performed on total cellular RNA extracted from
cell lines confirmed the presence of the predicted size AR
PCR products in AR transfectants but not Dzeo1 control
(Figure 1C). AR-specific primers were designed to amplify a
cDNA fragment corresponding to ligand-binding and DNA-
binding domains of the AR spanning seven exons. RT-PCR
for GAPDH expression served as a positive control. Western
blotting demonstrated a single band of 110 kDa correspond-
ing to the molecular weight of AR protein in both AR trans-
fectants but not in Dzeo1 control or the parental line DU145
(Figure 1D). The AR transfectants expressed similar levels of
AR protein. Under standard growth conditions, both AR
transfectants (DAR17 and DAR19) expressed cytoplasmic
and nuclear AR. The control, Dzeo1, did not express any
immunoreactivity to AR (data not shown).
Nuclear Translocation of AR in Response to DHT
Addition of 5 nM DHT to the culture medium resulted in a
rapid (from 15 minutes, maximal at 30 minutes) nuclear
translocation of the AR with minimal residual cytosolic
expression (Figure 2, A and B)—this effect could not be
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observed in either Dzeo1 or parental line DU145 (not
shown). The minimum concentration of DHT required for
complete translocation under standard conditions was 0.1
and 0.5 or 0.4 nM DHT for DAR17 or DAR19 transfectants,
respectively, when cells were grown in ssFBS (data not
shown). Treatment with physiological concentration (1 AM)
of 4-OH-F for 1 hour also resulted in nuclear translocation of
AR in DAR17 and DAR19 AR transfectants (data not shown).
Western blotting of DHT-treated (5 nM for 24 or 48 hours)
and nontreated AR transfectants did not show any demon-
strable alteration in the total cellular AR protein content
(Figure 2C) (i.e., both transfectants expressed similar levels
of AR protein after addition of DHT as before treatment).
Transfected AR is Transcriptionally Functional
Treatment with 5 nM DHT increased luc production in the
AR transfectants up to 25-fold compared to that of Dzeo1
(DAR17: P =0.003; DAR19: P=0.04) (Figure 2D). Addition
of 1 AM 4-OH-F did not induce any comparable activation of
MMTV luc in DAR17 and DAR19 (DAR17: P =0.08; DAR19:
P=0.15) (Figure 2D).
Ligand-Activated AR Results in Decreased
E-Cadherin Expression
ICC and FACS analysis demonstrated membranous with
some cytoplasmic E-cadherin expression in the majority of
Dzeo1 cells (f70%). Addition of 5 nM DHT or 1 AM 4-OH-F
had no effect on expression (DHT: P = 0.78; 4-OH-F:
P=0.8). Up to 55% of the cell population of DAR17 and
DAR19 expressed membranous with some cytoplasmic E-
cadherin when grown in standard culture conditions
(Figure 3A). Addition of 5 nM DHT to the cultures resulted
in a decrease of E-cadherin expressing cells to 30%
(DAR17: P =0.02; DAR19: P= 0.045) (Figure 3, B and C).
Addition of 4-OH-F did not affect the percentage of cell
surface expression of E-cadherin (Figure 3C). Results of
FACS analysis were normalized to levels of E-cadherin
expression in the LNCaP cell line.
Dzeo1, DAR17, and DAR19 cells exhibited identical
expression of a-catenin, which was found to be localized
mainly to the cell membrane with some cytoplasmic
expression, and addition of DHT did not affect either the
staining or the number of cells expressing a-catenin (data
not shown). A similar pattern was observed for h- and
g-catenin (data not shown).
AR Transfectants Exhibit DHT-Dependent Decreased
Cellular Aggregation
After 1 hour, 60% maximal aggregation was observed
in the Dzeo1 cell line, which was unaffected by treatment
of cells with DHT or 4-OH-F, alone or in combination
(Figure 4A). Similarly, no effect on cellular aggregation was
observed with the use of ssFBS during experiments.
Aggregation of DAR17 and DAR19 was diminished in
comparison with Dzeo1 (approximately 45% after 1 hour
vs 65% in Dzeo1; Figure 4, A–C). Cellular aggregation of
DAR17 and DAR19 was further reduced when the cells
were incubated with 5 nM DHT (about 35% during the
same time range; DAR17: P= 0.018; DAR19: P =0.01)
(Figure 4, B and C). AR transfectants treated with 4-
OH-F alone exhibited up to 65% aggregation (DAR17:
P=0.0007; DAR19: P =0.003) and treatment for 6 hours
with 4-OH-F prior to incubation with 5 nM DHT abrogated
the DHT-mediated reduction of aggregation with approx-
imately 60% of the population aggregated compared to
35% (when treated alone) (DAR17: P = 0.002; DAR19:
P=0.0002). Use of ssFBS in the growth media increased
the cellular aggregation of both DAR17 and DAR19 trans-
fectants, with approximately 65% of cells aggregated at
the end of 1 hour (P=0.01 and P =0.04, respectively)
(Figure 4, B and C).
As E-cadherin–mediated cell–cell adhesion requires
calcium ions, the experiments were repeated in Ca2+-free
conditions where there was virtually no aggregation of the
cells (data not shown). To further confirm that aggregation
was mediated by E-cadherin, blocking studies with
HECD1 anti–E-cadherin antibody were performed and
aggregation was reduced to less than 30% in all cell lines
(Dzeo1: P= 0.003; DAR17: P =0.003; DAR19: P =0.03)
(Figure 4D).
Figure 1. (A and B) Effect of 5 nM DHT on cellular morphology of AR and
control transfectants. Phase contrast microscopy of Dzeo1 control trans-
fectant (A) and DAR17 AR transfectant (B) grown on plastic in the presence
of 5 nM DHT. Dzeo1 cells show typical epithelioid morphology with close
cell – cell contacts, whereas in DAR17, the cells do not grow as tightly
together. (C) Ethidium bromide–stained PCR products. RT-PCR was
performed by utilizing AR- and GAPDH-specific primers on total cellular
RNA extracted from DAR17, DAR19, Dzeo1, and LNCaP cell lines. A single
AR-specific band is observed in the DAR17, DAR19, and in the positive
control LNCaP. The GAPDH bands indicate equal loading and optimal RT-
PCR. (D) A Western blot probed with anti-AR monoclonal antibody shows a
single 110-kDa AR reactive band in AR transfectants, DAR17 and DAR19,
and LNCaP (control) cell line. No AR-specific protein band was observed in
the control transfectant (Dzeo1) and the DU145 cell line.
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Figure 2. (A and B) Immunocytochemical localization of AR in DAR19 cells. In cells grown in the absence of DHT, AR expression is localized mainly to the
cytoplasm (A). Thirty minutes of treatment with 5 nM DHT results in a complete translocation of AR to the nucleus (B). All cells express nuclear AR but the intensity
of staining is heterogeneous. Nuclei stained with DAPI. (C) Immunoblotting using whole cell lysates containing equivalent quantity proteins (20 lg). A single 110-
kDa AR reactive band was observed in all lanes. Addition of 5 nM DHT (DAR/DHT) to the culture medium did not alter total AR protein content in either DAR17 or
DAR19. (D) DHT-dependent transactivation of the MMTV luc reporter plasmid in DAR17 and DAR19. In the absence of DHT, luc activity was only 2.5-fold
compared to Dzeo1. A 5-nM DHT treatment increased this 23- to 25-fold. Treatment with 1 lM 4-OH-F resulted in levels of luc activity in DAR17 and DAR19 similar
to controls (i.e., in the absence of DHT). Error bars represent meanFSD.
Androgens Modulate Cell Adhesion in Prostate Cancer Nightingale et al. 353
Neoplasia . Vol. 5, No. 4, 2003
DHT-Mediated Decrease of E-Cadherin in
Immunocomplexes of b- and c-Catenin
In Dzeo1, E-cadherin was found to be present in the
immunoprecipitates formed with E-cadherin, h-catenin, and
g-catenin antibodies, but not in those formed by a-catenin
antibody (Figure 5), suggesting that E-cadherin was com-
plexed with h- and g-catenin but not a-catenin. The relative
quantities of each protein were not changed by the addition
of DHT (Figure 5) or 1 AM 4-OH-F (data not shown).
Similarly, E-cadherin was identified in the immunopreci-
pitates formed by E-cadherin, h-catenin, and g-catenin anti-
bodies in DAR17 and DAR19 AR transfectants (Figure 5).
Addition of DHT to the growth medium resulted in a decrease
in the quantitative expression of E-cadherin associated with
g-catenin in immunoprecipitates of DAR17 transfectants and
h- and-g catenin in immunoprecipitates of DAR19, suggest-
ing a disruption of these complexes (Figure 5). Addition of
1 AM 4-OH-F gave results identical to standard growth
conditions (data not shown).
DHT-Mediated Growth Inhibition and Apoptosis
in AR Transfectants
Under standard growth conditions, there was no differ-
ence in cellular proliferation among DAR17, DAR19, and
Dzeo1. In the presence of 5 nM DHT, up to 40% decrease in
cellular proliferation was observed in DAR17 and DAR19
(DAR17 and DAR19: P=0.003) (Figure 6), with no change in
Dzeo1 (P=0.92).
FACS analysis revealed similar numbers of cells in each
stage of the cell cycle for DAR17, DAR19, and Dzeo1.
Supplementing the growth media with 5 nM DHT resulted
in an increase in the percentage of the cell population of
DAR17 and DAR19 in the G1 phase of the cell cycle and a
concomitant decrease in the numbers in the S and G2/M
phases (P=0.048 and P=0.032, respectively) but had no
effect on the Dzeo1 cells (P=0.57). These data suggest that
the DAR17 and DAR19 cells are still proliferating but are held
in G1 for a longer time than when grown under standard
culture conditions (Table 1).
Figure 3. (A and B) E-cadherin expression in DAR19 cells in the absence (A) and presence (B) of 5 nM DHT in the growth medium. Note a decrease in the
number of immunoreactive cells as well as a disruption of membranous expression of E-cadherin caused by 30-minute treatment (arrows). (C) The figure
summarizes the results of FACS analysis for E-cadherin expression in AR and control transfectants. The expression of E-cadherin in LNCaP, Dzeo1, DAR17,
and DAR19 was examined in cells grown in the absence or presence of DHT and 4-OH-F by FACS analysis. Percentage of positive cells from 5000 counted is
summarized as a graph. The graph shows a reduction in surface E-cadherin expression in DAR17 and DAR19 cells treated with 5 nM DHT (error barsFSD from
three independent experiments).
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Figure 4. Graphs show the results of aggregation assays conducted on AR transfectants and control transfectant over a period of 1 hour after exposing them to
different culture conditions (see Materials and Methods section). The cells were counted every 20 minutes and the ratio (number of single cells divided by the total
number of cells) is plotted against time. Error bars represent FSEM. (A) The graph shows no significant difference in Dzeo1 cellular aggregation under different
culture conditions. (B and C) Results of aggregation assays for DAR17 (B) and DAR19 (C) AR transfectants show significant differences (see text) between
aggregation of cells, which were incubated under different culture conditions. (D) Graphical representation of the cellular aggregation assay conducted after
incubating the control transfectant and AR transfectants in the presence (30 minutes prior to initiation of the assay) or absence of anti –E-cadherin blocking
antibody (HECD1). Cellular aggregation was reduced to less than 30% in Dzeo1 ( P = 0.003), DAR17 ( P= 0.03), and DAR19 ( P= 0.03).
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Occurrence of cell death, evidenced by nuclear fragmen-
tation, was observed in DAR17 and DAR19 when grown in
the presence of 5 nM DHT for over 144 hours (Figure 7,
A and B).
Trypan blue results indicated up to three-fold increase
in nonviable cells in DHT-treated AR transfectants at days
3 and 6 compared to DHT-free controls (DAR17 and
DAR19: P = 0.001) (Figure 7C). Dzeo1 did not exhibit
any difference in nonviable cell count in the presence
and absence of 5 nM DHT.
Results of cell death detection ELISA indicate the
presence of significantly higher levels (up to two-fold) of
histone-bound oligonucleosomes in DHT-treated AR trans-
fectants compared to nontreated controls (DAR17 and
DAR19: P=0.001) (Figure 7D). The control transfectant
did not show comparable difference in the levels of oligo-
nucleosomes in the presence or absence of 5 nM DHT
(P =0.84). These results substantiated those obtained by
trypan blue exclusion assay.
Discussion
We describe the generation of two stable androgen-respon-
sive AR transfectants from the AI DU145 human prostatic cell
line. AR transfectants expressed a functionally active AR,
which exhibited ligand (DHT)–mediated nuclear transloca-
tion on exposure to physiological concentrations of DHT. AR
nuclear translocation was seen over a range (60 pM–10 nM)
of DHT, with translocation observed at 15 minutes and
completed by 30 minutes. Nuclear transport of AR has been
previously demonstrated in studies utilizing prostatic and
nonprostatic cells [42,43]. Jenster et al. [43] demonstrated
Figure 5. E-cadherin/catenin complexes were immunoprecipitated using E-cadherin, a-catenin, b-catenin, and c-catenin antibodies after growth in normal
media and media supplemented with 5 nM DHT. Subsequent Western blotting used the alternative anti –E-cadherin (Transduction Laboratories) antibody. In
Dzeo1, E-cadherin levels were unaffected by addition of DHT, whereas in DAR17, a reduction in E-cadherin was observed in immunocomplexes of c-catenin and,
in DAR19, a reduction in E-cadherin was observed in immunocomplexes of b- and c-catenin following incubation with DHT. The antibodies used in
immunoprecipitation act as internal controls for protein concentration determination.
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cytosolic expression of unliganded AR in transiently trans-
fected Cos-1 and nuclear localization in HeLa cells. With the
addition of ligand, AR translocated to the nucleus in theCos-1
cells. They also demonstrated that the signal responsible for
nuclear import was encoded by the amino acid residues 608
to 625 and was functionally similar to the bipartite nucleo-
plasmin nuclear localization signal. AR transfected into Cos-7
cells also resulted in a cytoplasmically localized AR, and
nuclear transport occurred after addition of 50 nM DHT [42].
In comparison, we have shown that 60 pM DHT was required
for translocation and 100 pM DHT (f500 less) was suffi-
cient to induce complete nuclear translocation of theAR in our
stable transfectants.
We have also demonstrated that 5 nM DHT resulted in
AR-dependent activation of the MMTV luc reporter plasmid
and that 4-OH-F could not induce any comparable activation
of this reporter plasmid, despite the fact that the same dose of
4-OH-F induced complete AR nuclear translocation. 4-OH-F
has the capacity to bind to the AR, resulting in nuclear
translocation without transcriptionally activating the receptor.
Figure 6. Growth profiles of AR transfectants and controls were determined over a 5-day period in the presence and absence of 5 nM DHT using the MTT assay.
Results of cell proliferation are presented as percentage of DHT-free controls. There were no appreciable growth differences between AR transfectants and
controls in the absence of DHT. Addition of 5 nM DHT resulted in decreased cellular proliferation (up to 40%) in DAR17 and DAR19 compared to DHT-free controls.
The DU145 and Dzeo1 control transfectants exhibit a similar growth profile in the presence and absence of 5 nM DHT. Error bars represent FSD over three
independent experiments.
Table 1. Percentage of Cells in the Different Phases of the Cell Cycle, FSD, as Determined by FACS Analysis.
Dzeo1 Dzeo1+5 nM DHT DAR17 DAR17+5 nM DHT DAR19 DAR19+5 nM DHT
G1 60.7F0.1 59.8F4.9 74.2F4.5 81.6F1.5 78.6F5.2 86.2F4
S 13.7F0.4 13.2F2.8 7.6F1.1 6.8F1 7.2F0.7 3.6F0.1
G2/M 24.9F0.8 26.6F2.1 18F3.4 11.4F2.7 13.9F4.2 9.9F3.9
The data show that there is little difference in the percentage of cells in each stage of the cell cycle under standard growth conditions. However, addition of 5 nM
DHT to the media for 72 hours resulted in an increase in the percentage of DAR17 and DAR19 cells in the G1 phase of the cycle with a concomitant drop in S and
G2/M ( P=0.048 and P= 0.032, respectively), whereas Dzeo1 cells were unaffected ( P= 0.57).
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This has previously been demonstrated by Jenster et al. [43]
in transiently transfected Cos-1 and HeLa cells in which
antiandrogens and a range of steroid hormones induced
nuclear localization of the wild-type AR in a dose-dependent
way, without transcriptional activity. Collectively, these stud-
ies performed in epithelial cells of differing origins (kidney,
cervix, and prostate) demonstrate that the mechanisms
underlying ligand-mediated AR cytoplasmic to nuclear shut-
tling may be similar between androgens and antiandrogens.
Furthermore, nuclear translocation per se is insufficient for
transcriptional activity and is dependent on other factors
(conformational change, cofactors, etc.).
Following ligand activation, the presence of nuclear AR
protein could have been due to: 1) translocation of preformed
AR located in the cytoplasm, or 2) translocation of preformed
and de novo synthesized AR. Does ligand-mediated nuclear
translocation result in de novo protein synthesis? In order to
address this, cells were incubated in the presence of 50 Ag/
ml cycloheximide (a protein synthesis inhibitor, also used in
the investigations of nucleocytoplasmic shuttling) [44,45].
Growth of DAR17 and DAR19 in the presence of ligand
(DHT) and 50 Ag/ml cycloheximide resulted in cytoplasm
nuclear shuttling without de novo AR protein synthesis (data
not shown). The accumulation of the AR in the nucleus was
that of preformed cytoplasmic AR. Our observations are
consistent with those reported by Lin and Shain [46] and
Dai et al. [47]. Dai et al. showed increased AR protein levels
in transiently transfected PC3 cells but not in DU145 cells
despite increased mRNA in both cell lines. Lin and Shain
showed that exogenous ligand (testosterone) either
increased AR levels (two-fold to three-fold) or had no effect
in clonally derived rat PC cell lines. It is conceivable that
transcriptional and translational ligand-mediated regulation
of AR is cell line–specific.
In our study, both AR transfectants exhibited decreased
cohesive growth and addition of DHT increased this effect.
This was shown to be due to a decrease in E-cadherin
expression in these cells. Steroids (including androgens
and estrogens) have been reported to modulate cell–cell
adhesion in a tissue- and cell type–specific manner. For
example, estradiol increases E-cadherin mRNA levels in the
ovaries of immature mice and increases cadherin expression
in rat granulosa cells [48,49]. In endometrium, when cells
in the secretory phase are treated with estradiol, the levels
of E-cadherin and catenins are reduced [50]. The cell-to-cell
aggregation activity and the expressions of E-cadherin, and
a- and h-catenin mRNA in Ishikawa cells (derived from well-
differentiated endometrial cancer) were significantly sup-
pressed by estrogen, resulting in detachment of these cells
from the cultured surfaces [51].
AR expression in prostatic carcinoma cells has been
reported to suppress cell adhesion molecules [52].
Figure 7. (A and B) Photomicrographs showing nuclear fragmentation in 5 nM
DHT– treated AR transfectants (AR expression is predominantly nuclear).
Cells were grown in the presence of DHT for 3 days (A) (400) and 6 days
(B) (400) and ICC stained for AR. Black arrows indicate cells undergoing
apoptosis. (C) AR transfectants and controls were cultured in the presence
and absence of 5 nM DHT for 1, 3, and 6 days before trypan blue (0.4%) dye
exclusion testing. Cell were counted on a hemocytometer. Up to three-fold
higher nonviable, trypan blue–positive cells were present in DAR17 and
DAR19 incubated with 5 nM DHT compared to DHT-free controls at days 3
and 6. The control transfectant and the parental DU145 cell line did not exhibit
any appreciable differences. Results are presented as a percentage of DHT-
free controls. Error bars represent FSD over three independent experiments.
(D) Cell death detection ELISA was conducted on the lysates prepared from
AR transfectants and controls (parental DU145 and vector control trans-
fectant) at 1, 3, and 6 days (incubated in the presence or absence of 5 nM
DHT). Higher color absorbance values for DHT-treated AR transfectants at
days 3 and 6 indicated the presence of high levels (up to two-fold at days 3
and 6) of histone-bound oligonucleosomes compared to DHT-free controls.
Results are presented as percentage of control absorbance of DHT-free
controls. Errors bars represent FSD over three independent experiments.
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Bonaccorsi et al. [52] have reported that AR expression in
androgen-insensitive PC3 cells resulted in decreased
expression of a6h4 integrin. Androgens have been reported
to repress an epithelial cell adhesion molecule, C-CAM, in
the rat ventral prostate and seminal vesicle but not in other
androgen-dependent organs (the coagulating gland and the
dorsolateral prostate), or other organs (the liver and kidney)
[25]. These observations suggest that regulation of C-CAM
expression by androgen is tissue-specific. The exact mech-
anism by which AR and DHT are involved in E-cadherin
regulation needs further evaluation. It could be that AR
mediates transcriptional regulation of the E-cadherin pro-
moter in the AR transfectants. Hennig et al. have examined
the in vivo properties of the genomic E-cadherin promoter in
well and poorly differentiated carcinoma cell lines in order to
gain insights into the mechanisms of E-cadherin downregu-
lation in tumors. In vivo footprinting analysis revealed that
positive regulatory elements of the E-cadherin promoter
(a GC-rich region, the CCAAT box, and a palindromic
element) are specifically bound by transcription factors in
E-cadherin–expressing but not in E-cadherin–nonexpress-
ing cells [53]. Bussemakers et al. have isolated and charac-
terized the human E-cadherin gene promoter and have
studied the transcriptional regulation of this gene in two
human PC cell lines, one expressing E-cadherin (PC3) and
the other one not expressing E-cadherin (TSU-pr1). They
showed that the E-cadherin promoter is not active in the
nonexpressing cells and that this may be due to the binding
of a repressor protein to the promoter [54]. Transcriptional
regulation of steroid-responsive genes by steroid hormone
transcription factors, including the AR, is complex and also
dependent on accessory factors (i.e., coactivators or core-
pressors). In the present study, AR-mediated downregula-
tion of E-cadherin could be due to: 1) AR-dependent direct
transcriptional repression of E-cadherin promoter; 2) AR-
mediated transcriptional regulation through the binding of a
repressor protein (or repressor protein could itself be a part
of AR transcriptional complex); or 3) AR-dependent trans-
repression of another gene presumably involved in transcrip-
tional regulation of E-cadherin. Further studies are required
to elucidate DHT-mediated reduction in E-cadherin levels in
DAR17 and DAR19 AR transfectants by E-cadherin pro-
moter analysis.
From the immunoprecipitation data, it can be seen that
addition of DHT to the standard medium resulted in a
decrease in the quantitative expression of E-cadherin asso-
ciated with g-catenin in DAR17 and with h- and g-catenin
in DAR19. This suggests that there is a disruption of the
E-cadherin/catenin complex normally located at the cell
surface. Catenins are now known to involved in signalling
pathways including the Wnt-1 pathway and, generally,
these lead to either proteosomal degradation of h- and
g-catenin [55,56] or cytoplasmic stabilization and subse-
quent translocation to the nucleus, where they participate in
transactivation of Wnt-1–responsive genes such as C-MYC
[57–59]. However, in DAR17 and DAR19, there is no
reduction of expression of the catenins at the cell surface,
implying that they are neither cytoplasmically stabilized nor
degraded. It is possible that h- and g-catenin interact with
other molecules at the cell surface (e.g., MUC1 [60]), or are
diverted to other adhesion complexes (e.g. desmosomes
[61]), which would explain their continued presence at the
cell surface.
Clinical studies and both in vivo and in vitro exper-
imental works have clearly demonstrated that androgen
withdrawal results in inhibited proliferation and increased
apoptosis of androgen-sensitive prostatic cells [5,62,63].
Our results are paradoxical. Ligand stimulation of the
DAR17 and DAR19 resulted in: 1) decreased cellular
proliferation, and 2) increased apoptotic cell death. A
slower cellular proliferation in response to DHT has been
reported in three subclones (LNCaP-r and LNCaP-LNO
and LNCaP-FGC) of the LNCaP prostatic adenocarcinoma
cell line [64,65]. PC3 cells transfected with AR on expo-
sure to physiological concentration of DHT also showed
decreased cellular proliferation [66,67]. FACS analysis
data show that there is an increased number of DAR17
and DAR19 in G1 when treated with 5 nM DHT in
comparison to when grown under standard conditions,
and this could be due to an increase in cell cycle
molecules that negatively control G1–S transition such
as p21CIP1 and p27KIP1 [68–70]. Kokontis et al. observed
that at concentrations that repressed growth, androgen
transiently induced the expression of the cyclin-dependent
kinase (cdk) inhibitor p21waf1/cip1 in 104-R1 cells,
whereas expression of the cdk inhibitor p27KIP1 was
persistently induced by androgen in both 104-R1 and
104-R2 cells derived from LNCaP-FGC prostatic cancer
cell line by prolonged androgen deprivation [69]. Induced
expression of murine p27KIP1 in 104-R2 cells resulted in
G1 arrest. Lapointe and Labrie [70] have found a dose-
dependent DHT-induced inhibition of CAMA-1 breast can-
cer cells resulting in increase in p27KIP1. Recently, Geck
et al. [71] have demonstrated that androgen-induced pro-
liferative quiescence in PC cells is related to expression of
AS3 and its mediator, which belongs to a novel gene
family and a homologue of fungal proteins involved in
proliferation arrest.
Our results of androgen-induced apoptosis in AR trans-
fectants are consistent with the observations by Heisler et al.
[67], who reported that DHT treatment resulted in apoptotic
cell death of PC3 derived AR transfectants. However, in
comparison to their finding of apoptosis in all DHT-treated
cells, we observed cell death in only a fraction of DHT-
treated AR transfectants. This may be an adaptive response
in the continuous presence of ligand in the culture medium.
Dai et al. [47] have reported the desensitization of AR tran-
scriptional activity in LNCaP cells after prolonged (96 hours)
exposure to DHT. Androgen-induced apoptosis in AR trans-
fectants may also be secondary to decrease in E-cadherin
protein expression following DHT treatment. Previous stud-
ies have suggested that the loss or downregulation of
E-cadherin is associated with subsequent signalling for
apoptosis in cultured cells in vitro. Day et al. [72] have
reported that E-cadherin mediates aggregation-dependent
survival of prostate and mammary epithelial cells. They have
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shown increased E-cadherin expression in surviving cells in
response to protein kinase C–induced apoptosis, and block-
ing with E-cadherin–specific antibodies leads to synergistic
increase in apoptosis. Kantak and Kramer [73] have shown
that HSC3 human squamous carcinoma cells die by apop-
totic cell death when are they were grown in single
cell suspension cultures. However, if these cells are allowed
to form E-cadherin–mediated multicellular aggregates, they
not only survive but proliferate. These anchorage-independ-
ent survival and growth of HSC3 cells required high
levels of extracellular calcium and were inhibited with anti–
E-cadherin blocking antibody. These observations indicate
that E-cadherin–mediated intercellular adhesions generate
a compensatory mechanism that promotes growth and sup-
presses apoptosis.
Our study highlights a new mechanism of androgen-
mediated regulation of cell adhesion through E-cadherin in
human PC cells in vitro. This may well be relevant to
androgen-mediated human PC progression (invasion and
metastasis) in vivo. Further studies exploring downstream
signalling of AR and its relation to other pathways involved in
regulation of cell–cell adhesion, cell growth, and cell death
are needed to be undertaken to clarify the role and mecha-
nisms of AR-mediated signalling in PC.
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